Global Preclinical CRO Market Size, Share, Trends, COVID-19 Impact & Growth Forecast Report – Segmented By Service Type (Bioanalysis And DMPK Studies, Toxicology Testing And Other Preclinical Services), End User (Biopharmaceutical Companies, Government And Academic Institutes And Medical Device Companies) and Region (North America, Europe, Asia Pacific, Latin America, And Middle East & Africa) - Industry Analysis (2024 To 2029)

Updated On: January, 2024
ID: 6459
Pages: 175

Global Preclinical CRO Market Size (2024 to 2029)

The size of the global preclinical CRO market was worth USD 4.12 billion in 2023 and is estimated to grow at a CAGR of 8.3% from 2024 to 2029 and be worth USD 6.65 bn by 2029 from USD 4.46 billion in 2024.

Preclinical CRO produces a pharmaceutical item or medical equipment from the planning stages to treatment. It involves researchers, specialists, a healthy workforce, legislative and industry contacts, and other specialized innovative people. Before human clinical trials, the medicine must pass the preclinical preliminaries to ensure it is safe for human trials. Preclinical research is of prime importance and has various risks associated with it. It is the phase where there is a high chance that a product might fail, hence choosing a CRO. The preclinical CRO is vital in bringing a concept to the store for various biopharmaceutical organizations.

Global Preclinical CRO Market Drivers:

The latest interest of key market players in the field is supporting the preclinical CRO market growth. There has been continuous growth in the market due to the growing investments from key market players. For example, Albert Labs International Corp. signs a Letter of Intent (LOI) with a full-service Contract-Research Organization (CRO), iNGEN, to conduct the Company's first-in-human study of its leading drug target, KRN-101. Albert Labs International Corp. is a pharmaceutical drug development company focused on obtaining regulatory approval for novel medications to treat various mental health conditions. And RespireRx Pharmaceuticals Inc., a pioneer in the development of novel and ground-breaking therapies to treat illnesses brought on by disruption of neuronal signaling, is happy to announce that on November 14, 2022, the Company signed a letter of intent ("LOI") with a specialized clinical research organization with Australian headquarters that specializes in cannabinoid and psychedelic clinical research.

Global Preclinical CRO Market Restraints:

The regulations by animal rights protectors and animal testing restrictions are the major factors restraining the global market. For instance, in Europe, animal-based products or medicines are banned. Moreover, the rise in adopting alternative methods, such as micro-dosing hinders market growth. The preclinical CROs do not comply with international regulatory requirements like Good Laboratory Practice (GLP) standards, leading to quality issues, which is a major market challenge.

Impact of COVID-19 on the global preclinical CRO market:

COVID has affected all sectors in a significant way. Due to the coronavirus outbreak, the WHO has suggested all countries for a strict lockdown. More than 230 countries have implemented lockdowns, and all the companies and industries are closed, which has affected the world economy. The market has registered some losses during the pandemic. The pharmaceutical industries and medical device companies have paused the new trials due to strict lockdown regulations. The R&D investments for preclinical and clinical trials of the medicines are decreased. The pandemic led to a shift of focus from all other clinical research to vaccine development leading to significant losses for preclinical CROs. However, the market's key players are trying their best by investing in R&D to sustain the market competition.




Market Size Available

2023 to 2029

Base Year


Forecast Period

2024 to 2029

Segments Analysed

By Service Type, By End User

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Analysed

North America, Europe, Asia Pacific, Latin America, Middle East, and Africa

Key Market Players

Charles River Laboratories International, Inc., Laboratory Corporation of America, Envigo, Eurofins Scientific, PRA Health Science, Inc., Wuxi AppTec, Medpace, Inc., Pharmaceutical Product Development, LLC and Paraxel International Corporation.


This research report on the global preclinical CRO market has been segmented and sub-segmented based on service type, end-user, and region.

Global Preclinical CRO Market - By Service Type:

  • Bioanalysis And DMPK Studies        
  • Toxicology Testing
  • Other Preclinical Services  

Toxicology testing holds the largest market share in the preclinical CRO market based on service type. The rise in demand for new drugs and chemicals is boosting the market. Moreover, the growth in the outsourcing of non-core preclinical CRO studies and the adoption of toxicology tests fuel the market. 

Global Preclinical CRO Market - By End-user:

  • Biopharmaceutical Companies        
  • Government And Academic Institutes         
  • Medical Device Companies               

Based on end-user, Biopharmaceutical companies are the most significant end-user segment for preclinical CRO. The rise in outsourcing end-to-end services for pharmaceutical companies, primarily for small and mid-size companies, escalates the market's growth rate. In addition, the growth in drug entities based on rising competition has fuelled the market.

Global Preclinical CRO Market - By Region:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • The Middle East and Africa

Geographically, North America dominated the preclinical CRO market in 2023 and the lead of the North American region in the global market is anticipated to continue throughout the forecast period. The presence of a massive number of preclinical market players is the main reason North America's market growth. The key North American market contributors by the United States and Canada. According to, In 2020, approximately 45,400 preclinical studies were registered only in the United States. Further, pharmaceutical companies are interested in novel drug development for better treatment of chronic diseases, leading to North American market growth.

Asia-Pacific is predominantly rising during the forecast period. As a result, the size of the Asia Pacific preclinical CRO market was valued at USD 0.7 billion in 2020 and is estimated to be growing at a CAGR of 8.59%, reaching USD 1.06 billion by 2025 during the forecast period 2020-2025. India, China, and Japan are leading countries contributing to the Asia Pacific market share. The presence of numerous pharmaceutical companies in countries like India and China is the primary factor for market growth. Moreover, the increase in R&D investments and the secure government policies propels the Asia Pacific preclinical CRO market.


Some of the major companies dominating the global preclinical CRO market profiled in the report are Charles River Laboratories International, Inc., Laboratory Corporation of America, Envigo, Eurofins Scientific, PRA Health Science, Inc., Wuxi AppTec, Medpace, Inc., Pharmaceutical Product Development, LLC and Paraxel International Corporation.


  • In November 2022, complete service According to a press statement dated Nov. 9, French CRO signed the agreement with the cloud software provider to quicken database construction processes and minimize downtime that might occur during mid-study design adjustments. The contract's financial details weren't made public. However, Paul MacDonald, senior director of strategy at Veeva, stated in the press release that "effective data capture is key to running successful clinical trials." By streamlining study builds and trial execution for quicker development of new medicines, Excelya's addition of Veeva Vault EDC is a significant step in changing its approach to data management.
  • In November 2022, the patient data provider PhysIQ, specializing in patient monitoring and analytics, revealed its newest service for CROs, other life sciences research organizations, and drug developers. According to a press release from phyIQ on Nov. 9, the Intrepid Partner Program was created to broaden the Company's industry reach by enlisting CROs, academic research institutions, and other tech firms to utilize its portfolio of artificial intelligence-based digital biomarkers, experience working with government regulators, and other technologies in clinical operations.
  • In October 2022, A new AI-based platform was released by Phesi, a provider of clinical development analytics, which claims that customers will save an average of $7 million per phase 3 trial. According to a release from the Company on October 18, the platform, called Trial Accelerator, uses clinical study data to "deliver a comprehensive and consistent view of the patient throughout the process," enabling study teams to build better trials with a higher degree of success.
  • In October 2022, Exemplify BioPharma, a US-based CRO that offers integrated drug development services in Process & Analytical Chemistry and Formulation Development to pharmaceutical and biotech partners, was acquired by Symeres, a leading global drug discovery Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO). The management teams of both companies have cooperated with Keensight Capital, one of the top private equity managers focused on pan-European Growth Buyout investments1, which is also the majority shareholder in Symeres.

Please wait. . . . Your request is being processed

Frequently Asked Questions

How much is the global preclinical CRO market going to be worth by 2028?

As per our research report, the global preclinical CRO market size is projected to be USD 6.14 billion by 2028. 

At What CAGR, the global preclinical CRO market is expected to grow from 2023 to 2028?

The global preclinical CRO market is estimated to grow at a CAGR of 8.3% from 2023 to 2028. 

Which region is anticipated to witness considerable growth in the preclinical CRO market?

Geographically, the APAC preclinical CRO market is predicted to have the fastest growth rate in the global market from 2023 to 2028. 

Who are the key players operating in the preclinical CRO market?

Charles River Laboratories International, Inc., Laboratory Corporation of America, Envigo, Eurofins Scientific, PRA Health Science, Inc., Wuxi AppTec, and Medpace, Inc. are some of the key players operating the preclinical CRO market.

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1800

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample